Evidence map›Paper›PMID 42278529›Full record

ArticleInternational journal of molecular sciences2026

Tissue Effects of the Mitochondrial Division Inhibitor Mdivi-1 on the Substantia Nigra in a Laboratory Model of Dopaminergic System Damage.

Anna V Egorova, Dmitry N Voronkov, Maria S Ryabova, Alla V Stavrovskaya, Artem S Olshansky, Anastasia K Pavlova, Tatiana I Baranich, Dmitry A Kharlamov, Vladimir S Sukhorukov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna V EgorovaLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.ORCID 0000-0001-7112-2556
Dmitry N VoronkovLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.ORCID 0000-0001-5222-5322
Maria S RyabovaLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.
Alla V StavrovskayaLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.
Artem S OlshanskyLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.
Anastasia K PavlovaLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.
Tatiana I BaranichLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.
Dmitry A KharlamovV. F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children, 119620 Moscow, Russia.
Vladimir S SukhorukovLaboratory of Neuromorphology, Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia.ORCID 0000-0002-0552-6939

Funding

The Ministry of Education and Science of the Russian Federation 075-15-2024-638
6 · The paper itself

Abstract

The use of substances that modulate mitochondrial dynamics in cells of nervous tissue represents a new direction in targeted therapy for neurodegeneration. The aim of this study was to evaluate the effect of mitochondrial division inhibitor-1 (Mdivi-1) on neurons and microgliocytes of the substantia nigra under conditions of partial damage to the dopaminergic system. This study was conducted using the 6-hydroxydopamine model of parkinsonism in rats; a separate experimental group of animals received Mdivi-1 intraperitoneally at a dose of 20 mg/kg for 5 days. The intensity of immunofluorescence staining for Tomm20, MTCO1, pDrp1, and Mfn2 was evaluated in neurons of the substantia nigra, and microglial activation was morphologically assessed. It was found that unilateral administration of 6-OHDA led to pro-inflammatory changes in microglia and changes in mitochondrial markers of neurons on the side of the substantia nigra contralateral to the toxin injection. Mdivi-1 did not affect the damage and mitochondrial proteins of neurons in pars compacta of the substantia nigra; however, it changed mitochondrial markers in nervous cells of the pars reticulata. The use of Mdivi-1 to address abnormal processes in neurodegeneration requires additional studies that include a differential assessment of its effects on various cell types.

Indexed as

DopamineDopaminergic NeuronsQuinazolinonesSubstantia NigraAnimalsDisease Models, AnimalMaleMicrogliaMitochondriaMitochondrial DynamicsOxidopamineRatsRats, Wistar3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinoneDopamineOxidopamineQuinazolinones6-hydroxydopamineMdivi-1microgliamitochondrial dynamicsParkinson’s diseasesubstantia nigra

Identifiers

PMID42278529
PMCPMC13256210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.